BMEA Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 15.45%, SMA50 10.56%, SMA200 -10.1%). The stock’s 14-day RSI is 61.5 (firm momentum), while the ATR of 0.1 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -52.92% below its high and over 66.3% above its low. Average 10-day trading volume of 3.22 million shares is significantly above the 3-month average of 1.48 million, indicating heightened recent market interest.

Biomea Fusion, Inc. generated EPS of -$2.39 over the past year. Five-year average earnings growth is -149.32%. Wall Street analysts project EPS growth of 29.3% annually over the next five years. The latest quarter delivered EPS of -$0.12. The next quarter is forecast at -$0.23. Next year's EPS is expected at -$8.32. Analyst sentiment is bullish. Analyst rating data shows there are 1 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $16.00 to $6.00. The high target offers 1112.12% upside. The low target suggests 354.55% downside. The mean target is $11.82. This offers 795.45% upside. Biomea Fusion, Inc. earnings surprise history is a mixed track record. The quarter that ended August 06, 2026, missed forecasts by -46.3%. The prior quarter beat by -29.17%. Over the last six quarters, Apple has recorded several small beats. These include -4.76% in May 05, 2025.

Biomea Fusion, Inc. has 72.30 million shares outstanding. The public float is 67.63 million shares, elevated short interest at 20.10% of float. This equals 11.95 million shares. The short ratio is 8.24 days. Institutional investors hold 42.15% of the float. Insiders own 7.17%. Stergiopoulos Sotirios holds 4.40 million shares, Chen Bihua has 3.57 million shares and A2A Pharmaceuticals, Inc. has 3.50 million shares.

Biomea Fusion, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.04. This means the shares are trading above this model’s fair value.

Biomea Fusion, Inc. (NASDAQ:BMEA) closed at $1.32 USD, losing -$0.17 (-11.41%) from the previous close of $1.49. The stock is currently mid-range between its 52-week high and low $0.87 and $2.99. With a market capitalization of about $95.44 million, Biomea Fusion, Inc. is classified as a micro-cap and shows lower-than-market volatility (beta ~-0.30). Key stats such as the average daily volume over the past year has been around 1.49 million shares, trading with heavier-than-usual volume. Headquartered in San Carlos, CA, Biomea Fusion, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Michael J. Hitchcock, the company employs approximately 37 people and listed since April 16, 2021. Biomea Fusion, Inc., a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.

Biomea Fusion, Inc. trades at a P/E ratio of -2.66, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 7.87 trading at moderately above to book value. The P/FCF stands at -2.03, also below market averages.

Our AI price prediction model suggests that Biomea Fusion, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 3-Month Outlook: Projected fall of -89.39%, reaching $0.14 by December 24, 2026, with a range of $0.08 to $0.22. 1-Year Outlook: Projected gain of 296.21%, with price at $5.23 by September 24, 2027, within a range of $0.00 to $4.05.

Biomea Fusion, Inc. (NASDAQ:BMEA) shares are up 11.29% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biomea Fusion, Inc. trading at a premium to the broader market with a P/E of -2.66. Analyst sentiment is cautious, with the majority of ratings in Market Outperform territory and a mean price target of $35.03, suggesting 2553.79% upside.